SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in an ovarian cancer murine xenograft model

被引：0
|
作者：
Bauerschlag, D. O.
Schem, C.
Tiwari, S.
Meinhold-Heerlein, I.
Mundhenke, C.
Weigel, M.
Egberts, J. H.
Kalthoff, H.
Jonat, W.
Maass, N.
机构：
[1] Univ Hosp Kiel Germany, Kiel, Germany
[2] Univ Hosp, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.16557
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16557
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma - NCIC CTG IND 185
    Biagi, J. J.
    Oza, A. M.
    Grimshaw, R.
    Ellard, S. L.
    Lee, U.
    Sederias, J.
    Ivy, S. P.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model
    Mahller, Yonatan Y.
    Vaikunth, Sachin S.
    Currier, Mark A.
    Miller, Shyra J.
    Ripberger, Maria C.
    Hsu, Ya-Hsuan
    Mehrian-Shai, Ruty
    Collins, Margaret H.
    Crombleholme, Timothy M.
    Ratner, Nancy
    Cripe, Timothy P.
    MOLECULAR THERAPY, 2007, 15 (02) : 279 - 286
  • [33] The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling
    Ikezoe, Takayuki
    Nishioka, Chie
    Tasaka, Taizo
    Yang, Yang
    Komatsu, Naoki
    Togitani, Kazuto
    Koeffler, H. Phillip
    Taguchi, Hirokuni
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (10) : 2522 - 2530
  • [34] Vascular Endothelial Growth Factor (VEGF) Receptor Inhibitors, SU11248 and SU5416, Directly Inhibit the Proliferation of Cultured ER-positive and ER-negative Human Breast Cancer Cells
    Wells, Jeremy
    Young, Emily
    Tucker, Kevan
    Chawla, Simran
    Gu, Jian-Wei
    FASEB JOURNAL, 2009, 23
  • [35] Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
    O. Guérin
    P. Formento
    C. Lo Nigro
    P. Hofman
    J. L. Fischel
    M. C. Etienne-Grimaldi
    M. Merlano
    J. M. Ferrero
    G. Milano
    Journal of Cancer Research and Clinical Oncology, 2008, 134 : 51 - 57
  • [36] Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel.: A new therapeutic perspective in hormone refractory prostate cancer
    Guerin, O.
    Formento, P.
    Lo Nigro, C.
    Hofman, P.
    Fischel, J. L.
    Etienne-Grimaldi, M. C.
    Merlano, M.
    Ferrero, J. M.
    Milano, G.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (01) : 51 - 57
  • [37] SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer
    Abrams, TJ
    Lee, LB
    Murray, LJ
    Pryer, NK
    Cherrington, JM
    MOLECULAR CANCER THERAPEUTICS, 2003, 2 (05) : 471 - 478
  • [38] Safety and efficacy of sunitinib malate (SU11248) as second-line therapy in metastatic breast cancer (MIBC) patients: preliminary results from a Phase II study
    Miller, K. D.
    Burstein, H. J.
    Elias, A. D.
    Rugo, H. S.
    Cobleigh, M. A.
    Wolff, A. C.
    Eisenberg, R. D.
    Collier, M.
    Adams, B. J.
    Baum, C. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 113 - 114
  • [39] Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer
    Park, Brian Y.
    Grisham, Rachel N.
    den Hollander, Bjornar
    Thapi, Dharmarao
    Berman, Tara
    de Stanchina, Elisa
    Zhou, Qin
    Iyer, Gopa
    Aghajanian, Carol
    Spriggs, David R.
    CANCER INVESTIGATION, 2016, 34 (10) : 517 - 520
  • [40] NOVEL TUMOR SUPPRESSORS INHIBIT TUMOR GROWTH AND ANGIOGENESIS IN GYNECOLOGICAL CANCER
    Lee, Je-Ho
    JOURNAL OF GENE MEDICINE, 2009, 11 (12): : 1143 - 1143
12345